The FDA’s Manufacturing Flexibilities for Cell and Gene Therapies Guidance – Another Cog in the Nebulous Machine

Boyds Director of Regulatory Affairs, Dr Eric Hardter, dives deep into the FDA’s manufacturing flexibilities for cell and gene therapies guidance.